intravesical administration

Summary

Summary: The instillation or other administration of drugs into the bladder, usually to treat local disease, including neoplasms.

Top Publications

  1. ncbi Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials
    Richard J Sylvester
    European Organisation for Research and Treatment of Cancer Data Center, Brussels, Belgium
    J Urol 168:1964-70. 2002
  2. ncbi BCG dose reduction by decreasing the instillation frequency: effects on local Th1/Th2 cytokine responses in a mouse model
    Elizabeth C De Boer
    Department of Urology, Academic Medical Center University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Eur Urol 48:333-8. 2005
  3. ncbi Effect of intravesical Resiniferatoxin (RTX) on lower urinary tract symptoms, urodynamic parameters, and quality of life of patients with urodynamic increased bladder sensation
    Apostolos Apostolidis
    The National Hospital for Neurology and Neurosurgery, Department of Uro Neurology, Internal mailbox 71, Queen Square, London WC1N 3BG, UK
    Eur Urol 50:1299-305. 2006
  4. ncbi Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update
    M Craig Hall
    American Urological Association Education and Research, Inc, USA
    J Urol 178:2314-30. 2007
  5. ncbi Do prognostic parameters of remission versus relapse after Bacillus Calmette-Guérin (BCG) immunotherapy exist?. analysis of a quarter century of literature
    Fabien Saint
    Urology Department, Groupe d Etude des Tumeurs Urologiques GETU, Hopital Henri Mondor, 94000, Creteil, France
    Eur Urol 43:351-60; discussion 360-1. 2003
  6. ncbi Urodynamic effect of intravesical resiniferatoxin in patients with neurogenic detrusor overactivity of spinal origin: results of a double-blind randomized placebo-controlled trial
    Carlos Silva
    Department of Urology, Hospital S Joao, 4200 319 Porto, Portugal
    Eur Urol 48:650-5. 2005
  7. ncbi The effect of intravesical resiniferatoxin in patients with idiopathic detrusor instability suggests that involuntary detrusor contractions are triggered by C-fiber input
    Carlos Silva
    Department of Urology, Hospital São João and Institute of Histology and Embryology, Faculty of Medicine of Porto and Institute of Biologia Molecular Celular, University of Porto, Porto, Portugal
    J Urol 168:575-9. 2002
  8. ncbi Therapeutic effect of multiple resiniferatoxin intravesical instillations in patients with refractory detrusor overactivity: a randomized, double-blind, placebo controlled study
    Hann Chorng Kuo
    Department of Urology, Buddhist Tzu Chi General Hospital and Buddhist Tzu Chi University School of Medicine, Hualien, Taiwan, Republic of China
    J Urol 176:641-5. 2006
  9. ncbi Saline volume in transvesical intra-abdominal pressure measurement: enough is enough
    J De Waele
    Ghent University Hospital, Intensive Care Unit 1K12 C, De Pintelaan 185, 9000, Ghent, Belgium
    Intensive Care Med 32:455-9. 2006
  10. ncbi Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer
    O N Gofrit
    Department of Urology, Hadassah University Hospital, Jerusalem, Israel
    Urology 63:466-71. 2004

Detail Information

Publications201 found, 100 shown here

  1. ncbi Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials
    Richard J Sylvester
    European Organisation for Research and Treatment of Cancer Data Center, Brussels, Belgium
    J Urol 168:1964-70. 2002
    ..We determine if intravesical bacillus Calmette-Guerin (BCG) reduces the risk of progression after transurethral resection to stage T2 disease or higher in patients with superficial (stage Ta, T1 or carcinoma in situ) bladder cancer...
  2. ncbi BCG dose reduction by decreasing the instillation frequency: effects on local Th1/Th2 cytokine responses in a mouse model
    Elizabeth C De Boer
    Department of Urology, Academic Medical Center University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Eur Urol 48:333-8. 2005
    ....
  3. ncbi Effect of intravesical Resiniferatoxin (RTX) on lower urinary tract symptoms, urodynamic parameters, and quality of life of patients with urodynamic increased bladder sensation
    Apostolos Apostolidis
    The National Hospital for Neurology and Neurosurgery, Department of Uro Neurology, Internal mailbox 71, Queen Square, London WC1N 3BG, UK
    Eur Urol 50:1299-305. 2006
    ..We investigated the efficacy of intravesical RTX in patients with urgency and frequency due to increased bladder sensation...
  4. ncbi Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update
    M Craig Hall
    American Urological Association Education and Research, Inc, USA
    J Urol 178:2314-30. 2007
  5. ncbi Do prognostic parameters of remission versus relapse after Bacillus Calmette-Guérin (BCG) immunotherapy exist?. analysis of a quarter century of literature
    Fabien Saint
    Urology Department, Groupe d Etude des Tumeurs Urologiques GETU, Hopital Henri Mondor, 94000, Creteil, France
    Eur Urol 43:351-60; discussion 360-1. 2003
    ..To review prognostic factors identified in clinical trials for remission versus relapse after intravesical adjuvant Bacillus Calmette-Guérin (BCG) immunotherapy for superficial bladder cancer (Ta, T1, and carcinoma in situ)...
  6. ncbi Urodynamic effect of intravesical resiniferatoxin in patients with neurogenic detrusor overactivity of spinal origin: results of a double-blind randomized placebo-controlled trial
    Carlos Silva
    Department of Urology, Hospital S Joao, 4200 319 Porto, Portugal
    Eur Urol 48:650-5. 2005
    ..To access by a placebo-controlled randomized clinical trial the effect of intravesical resiniferatoxin on the urodynamic parameters of patients with neurogenic detrusor overactivity (NDO) of spinal origin...
  7. ncbi The effect of intravesical resiniferatoxin in patients with idiopathic detrusor instability suggests that involuntary detrusor contractions are triggered by C-fiber input
    Carlos Silva
    Department of Urology, Hospital São João and Institute of Histology and Embryology, Faculty of Medicine of Porto and Institute of Biologia Molecular Celular, University of Porto, Porto, Portugal
    J Urol 168:575-9. 2002
    ..We evaluated the role of bladder C-fiber input in involuntary detrusor activity in patients with idiopathic detrusor instability...
  8. ncbi Therapeutic effect of multiple resiniferatoxin intravesical instillations in patients with refractory detrusor overactivity: a randomized, double-blind, placebo controlled study
    Hann Chorng Kuo
    Department of Urology, Buddhist Tzu Chi General Hospital and Buddhist Tzu Chi University School of Medicine, Hualien, Taiwan, Republic of China
    J Urol 176:641-5. 2006
    ..In this randomized, double-blind, placebo controlled study we evaluated the therapeutic effects of this resiniferatoxin treatment...
  9. ncbi Saline volume in transvesical intra-abdominal pressure measurement: enough is enough
    J De Waele
    Ghent University Hospital, Intensive Care Unit 1K12 C, De Pintelaan 185, 9000, Ghent, Belgium
    Intensive Care Med 32:455-9. 2006
    ..The objective was to determine the minimum volume of instillation fluid for intra-abdominal pressure (IAP) measurement, and to evaluate the effect of instillation volume on transvesically measured IAP...
  10. ncbi Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer
    O N Gofrit
    Department of Urology, Hadassah University Hospital, Jerusalem, Israel
    Urology 63:466-71. 2004
    ..To evaluate the effectiveness of combined local bladder hyperthermia and intravesical chemotherapy for the treatment of patients with high-grade (G3) superficial bladder cancer...
  11. ncbi Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response
    Antoine G van der Heijden
    University Medical Centre Nijmegen, Nijmegen, The Netherlands
    J Urol 176:1349-53; discussion 1353. 2006
    ..We studied the ablative activity of intravesical apaziquone (EOquin) on a papillary marker tumor and determined the incidence of side effects...
  12. ncbi Short-schedule intravesical gemcitabine with ablative intent in recurrent Ta-T1, G1-G2, low- or intermediate-risk, transitional cell carcinoma of the bladder
    Massimo Maffezzini
    Struttura Complessa di Urologia, E O Ospedali Galliera, Genova, Italy
    Eur Urol 51:956-61. 2007
    ..to assess ablative efficacy and tolerability of short-schedule intravesical gemcitabine for intact, low- and intermediate-risk, recurrent superficial bladder tumours...
  13. ncbi Whole bladder photodynamic therapy for orthotopic superficial bladder cancer in rats: a study of intravenous and intravesical administration of photosensitizers
    Zhengwen Xiao
    Department of Oncology, University of Alberta, Edmonton, Alberta, Canada
    J Urol 169:352-6. 2003
    ....
  14. ncbi Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC)
    Paolo Gontero
    Department of Medical Sciences, Urology Clinic, University of Piemonte Orientale, Via Solaroli, 17, 28100 Novara, Italy
    Eur Urol 46:339-43. 2004
    ..The purpose of the present study was to investigate the ablative efficacy of intravesical Gemcitabine on intermediate-risk SBC...
  15. ncbi Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder
    Guido Dalbagni
    Department of Urology, Division of Epidemiology and Biostatistics, The Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:2729-34. 2006
    ..The aim of this phase II study was to determine the efficacy of gemcitabine administered as an intravesical agent in patients with bacille Calmette-Guérin (BCG) -refractory transitional cell carcinoma of the bladder...
  16. ncbi Phase 1 study of the intravesical administration of recombinant human interleukin-12 in patients with recurrent superficial transitional cell carcinoma of the bladder
    Geoffrey R Weiss
    The University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, USA
    J Immunother 26:343-8. 2003
    ..In summary, intravesical rhIL-12 was well tolerated by patients with recurrent STCC but showed no clinically relevant evidence of antitumor or immunologic effects...
  17. ncbi Synergistic antitumor activity by combined treatment with gemcitabine and antisense oligodeoxynucleotide targeting clusterin gene in an intravesical administration model against human bladder cancer kotcc-1 cells
    Hideaki Miyake
    Department of Urology, Hyogo Medical Center for Adults, Akashi and Kobe University School of Medicine, Kobe, Japan
    J Urol 171:2477-81. 2004
    ....
  18. ncbi Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder
    Guido Dalbagni
    Department of Urology, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 20:3193-8. 2002
    ..The aim of this phase I study was to determine the safety and toxicity profile of gemcitabine administered as an intravesical agent in patients with transitional-cell carcinoma (TCC) of the bladder...
  19. ncbi Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance
    T R L Griffiths
    University Urology Unit, Freeman Hospital, Newcastle upon Tyne, United Kingdom
    J Urol 167:2408-12. 2002
    ..We report the outcome of primary carcinoma in situ and carcinoma in situ associated with Ta or T1 transitional cell carcinoma of the bladder treated with BCG...
  20. ncbi Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study
    Menachem Laufer
    Department of Urology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, MD, USA
    J Clin Oncol 21:697-703. 2003
    ..To determine maximum-tolerated dose, toxicities, and pharmacokinetics associated with weekly intravesical gemcitabine therapy in patients with superficial bladder cancer...
  21. ncbi Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a Phase II prospective multicenter study
    Riccardo Bartoletti
    Department of Urology, University of Florence, Florence, Italy
    Urology 66:726-31. 2005
    ..To determine the tolerability and efficacy after 1 year of weekly intravesical gemcitabine therapy in patients with intermediate-risk and high-risk superficial transitional cell carcinoma...
  22. ncbi [Sepsis and multiple organ failure after BCG-instillation for bladder cancer]
    A Elmer
    Medizinische Klinik I und II, St Josefs Hospital, Wiesbaden
    Internist (Berl) 45:935-9. 2004
    ..The patient developed severe sepsis and suffered from multiple organ failure. Despite partial improvement, the course was complicated by intracranial sinus thrombosis, and the patient died two month after admission...
  23. ncbi Granulomatous hepatitis after intravesical BCG treatment for bladder cancer
    Osman Ersoy
    Department of Gastroenterology, Hacettepe University Faculty of Medicine, Ankara, Turkey
    Indian J Gastroenterol 25:258-9. 2006
    ..One of them was treated successfully with antitubercular therapy; the other died because of BCG sepsis and multi-organ failure...
  24. ncbi Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study
    Antonella Giannantoni
    Department of Urology, University of Perugia, Perugia, Italy
    J Urol 172:240-3. 2004
    ..St. Louis, Missouri) and botulinum-A toxin injections into the detrusor muscle in a group of spinal cord injured patients with neurogenic detrusor overactivity unresponsive to conventional anticholinergic therapy...
  25. ncbi LPS-sensory peptide communication in experimental cystitis
    M R Saban
    Department of Physiology, The University Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73190, USA
    Am J Physiol Renal Physiol 282:F202-10. 2002
    ..These findings suggest that LPS amplifies neurogenic inflammation, thereby playing a role in the pathogenesis of neurogenic cystitis...
  26. ncbi [Acute respiratory failure and septic shock induced by Mycobacterium bovis. A rare side effect of intravesical BCG therapy]
    Gilles Rival
    Universite Francois Rabelais, Réanimation Médicale, CHU Bretonneau, Tours 37
    Presse Med 35:980-2. 2006
    ..Intravesical bacillus Calmette-Guerin (BCG) therapy, recommended for superficial bladder tumors, triggers side effects in fewer than 5% of patients. The most severe side effects, however, are septic shock and acute respiratory failure...
  27. ncbi Diffuse granulomatous mesenteric disease caused by intravesical bacillus Calmette-Guérin instillation masquerading as peritoneal carcinomatosis
    Andrew Shapiro
    Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Urol Oncol 23:352-3. 2005
    ..This patient was thought to have peritoneal carcinomatosis. One must be cognizant of the possibility when evaluating patients with similar findings and images after bacillus Calmette-Guérin therapy...
  28. ncbi Phase I/II pilot study of intravesical apaziquone (EO9) for superficial bladder cancer
    Rajiv Puri
    Department of Urology, Bradford Royal Infirmary, Bradford, United Kingdom
    J Urol 176:1344-8. 2006
    ..We determined the dose of apaziquone that can be safely administered intravesically and explored its activity for superficial bladder transitional cell carcinoma...
  29. ncbi The use of valrubicin for the chemoresection of superficial bladder cancer -- a marker lesion study
    D W Newling
    Academisch Ziekenhuis der Vrije Universiteit, Amsterdam, The Netherlands
    Eur Urol 39:643-7. 2001
    ..To assess the effect and tolerance of a 6-week course of intravesical valrubicin on a tumour intentionally left in the bladder (marker lesion) following incomplete transurethral resection of the bladder (TURBT)...
  30. ncbi Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-uri
    A P van der Meijden
    Bosch Medicentrum, s'Hertogenbosch, University of Maastricht, The Netherlands
    J Urol 166:476-81. 2001
    ..Further followup is required before long-term conclusions can be made for progression-to-muscle invasive disease and survival...
  31. ncbi Novel insights into the mechanism of action of intravesical immunomodulators
    Dionisios N Mitropoulos
    1st Department of Urology, Athens Medical School, Athens, Greece
    In Vivo 19:611-21. 2005
    ..Tumor cell killing is mediated through FasLigand, perforin and TNF-alpha. In a recent study, we found that BCG up-regulated iNOS expression in normal human urothelium in vivo, suggesting a role for NO in BCG-mediated antitumor activity...
  32. ncbi Fatal systemic reaction after multiple doses of intravesical bacillus Calmette-Guérin for polyposis
    H Peyriere
    Center of Pharmacovigilance, Saint Charles Hospital, Montpellier, France
    Ann Pharmacother 34:1279-82. 2000
    ..To report a case of fatal systemic reaction after intravesical administrations of bacillus Calmette-Guérin (BCG) for polyposis...
  33. pmc Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer
    Masaki Nogawa
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto, Japan
    J Clin Invest 115:978-85. 2005
    ..We believe intravesical siRNA instillation against bladder cancer will be useful as a therapeutic tool...
  34. ncbi Isolated renal tuberculosis following intravesical Bacillus Calmette-Guérin therapy for bladder cancer
    Yoshihiro Wada
    Department of Urology, Kumamoto University School of Medicine, Kumamoto, Japan
    Urol Int 72:257-60. 2004
    ....
  35. ncbi The role of granulocytes following intravesical BCG prophylaxis
    Salvatore Siracusano
    Department of Urology, Trieste University, Trieste, Italy
    Eur Urol 51:1589-97; discussion 1597-9. 2007
    ..The number of polymorphonuclear neutrophils (PMNs) and urothelial cells (UCs) was evaluated. We examined the in vitro response of the T24 UC line to human PMNs after BCG treatment...
  36. ncbi Late occurrence of bilateral tuberculous-like epididymo-orchitis after intravesical bacille Calmette-Guérin therapy for superficial bladder carcinoma
    C Falkensammer
    Department of Urology, University of Innsbruck, Innsbruck, Austria
    Urology 65:175. 2005
    ..This case demonstrates the late adverse effects that can occur after intravesical BCG therapy, which in our patient ended in surgical removal of both gonads...
  37. ncbi [Two cases of successful treatments with steroid for local and systemic hypersensitivity reaction following intravesical instillation of Bacillus Calmette-Guerin]
    N Shimasaki
    Department of Urology, Kochi Medical School
    Hinyokika Kiyo 47:281-4. 2001
    ..The signs and symptoms mentioned above were decreased immediately and disappeared after the second steroid pulse therapy...
  38. ncbi Parallel changes in bladder suburothelial vanilloid receptor TRPV1 and pan-neuronal marker PGP9.5 immunoreactivity in patients with neurogenic detrusor overactivity after intravesical resiniferatoxin treatment
    C M Brady
    Department of Uro Neurology, Institute of Neurology, Queen Square, London, UK
    BJU Int 93:770-6. 2004
    ..5-staining nerve fibres decrease in patients with spinal NDO who respond to intravesical capsaicin, and TRPV1 is present on these suburothelial nerve fibres in normal and overactive human urinary bladder...
  39. ncbi A phase I study of intravesical suramin for the treatment of superficial transitional cell carcinoma of the bladder
    Edward M Uchio
    Urologic Oncology Therapeutic Branch, Center for Cancer Research, National Cancer Institute NIH, Bethesda, MD, USA
    J Urol 169:357-60. 2003
    ....
  40. ncbi Intravesical administration of gemcitabine in superficial bladder cancer: a phase I study with pharmacodynamic evaluation
    E De Berardinis
    Department of Urology, U Bracci, University of Rome La Sapienza, Rome, Italy
    BJU Int 93:491-4. 2004
    ..To determine, in a phase I trial, the local and systemic toxicity and pharmacodynamics of intravesical gemcitabine in patients with superficial bladder cancer...
  41. ncbi Cytokine gene expression in a mouse model: the first instillations with viable bacillus Calmette-Guerin determine the succeeding Th1 response
    Elizabeth C De Boer
    Department of Urology, Academic Medical Centre University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    J Urol 170:2004-8. 2003
    ..These studies may provide a rationale for possible modifications of the established clinical treatment protocol...
  42. ncbi Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma
    Renzo Colombo
    Department of Urology, University Vita Salute, San Raffaele Hospital, Via Olgettina 60, 20132 Milan, Italy
    J Clin Oncol 21:4270-6. 2003
    ....
  43. ncbi Immunostimulation in the urinary bladder by local application of Nocardia rubra cell-wall skeletons (Rubratin) and bacillus Calmette-Guérin as therapy for superficial bladder cancer: a comparative study
    E C De Boer
    Department of Urology, University of Amsterdam, The Netherlands
    Clin Infect Dis 31:S109-14. 2000
    ....
  44. ncbi Intravesical administration of gammadelta T cells successfully prevents the growth of bladder cancer in the murine model
    Takeshi Yuasa
    Department of Urology, Akita University School of Medicine, Akita, 010 8543, Japan
    Cancer Immunol Immunother 58:493-502. 2009
    Superficial bladder cancers are usually managed with transurethral resection followed by the intravesical administration of Bacillus Calmette-Guerin which requires major histocompatibility complex (MHC) class I expression on cancer cells...
  45. ncbi The role of bladder afferent pathways in bladder hyperactivity induced by the intravesical administration of nerve growth factor
    Y C Chuang
    Department of Pharmacology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    J Urol 165:975-9. 2001
    ..evaluated the role of Adelta and C fiber afferents in the type of bladder hyperactivity induced by the intravesical administration of nerve growth factor...
  46. pmc Polarisation of a T-helper cell immune response by activation of dendritic cells with CpG-containing oligonucleotides: a potential therapeutic regime for bladder cancer immunotherapy
    H Atkins
    Northern Institute for Cancer Research, School of Surgical and Reproductive Sciences, Faculty of Medical Sciences, University of Newcastle, Framlington Place, Newcastle upon Tyne NE2 4HH, UK
    Br J Cancer 89:2312-9. 2003
    ..Given the toxicity of LPS, our data suggest that CpG-oligonucleotides may be beneficial for intravesical therapy of bladder cancer...
  47. ncbi The effect of fasting or desmopressin before treatment on the concentration of mitomycin C during intravesical administration
    A M Cliff
    Wirral Hospital NHS Trust, Upton, Wirral, UK
    BJU Int 86:644-7. 2000
    ....
  48. pmc Local immunostimulation induced by intravesical administration of autologous interferon-gamma-activated macrophages in patients with superficial bladder cancer
    F Pages
    Hopital Europeen Georges Pompidou, Service d Immunologie Biologique, Unité Inserm 255, France
    Clin Exp Immunol 127:303-9. 2002
    We conducted a phase I/II clinical trial of the safety and efficacy of intravesical administration of autologous IFN-gamma-activated macrophages (MAK) in patients with superficial bladder cancer...
  49. ncbi Intravesical gemcitabine in recurrent superficial bladder carcinoma: preliminary results on ablative efficacy and tolerability
    Fabio Campodonico
    Department of Urology, Galliera Hospital, 14 Mura delle Cappuccine, 16128 Genoa, Italy
    Anticancer Res 25:2381-4. 2005
    ..The ablative potential and toxicity of gemcitabine, administered intravesically in low stage and grade superficial transitional cell carcinoma (TCC), were evaluated...
  50. ncbi [Treatment of Bacillus Calmette-Guerin refractory superficial bladder cancer: further intravesical therapy]
    Yasuo Kohjimoto
    The Department of Urology, Wakayama Medical University
    Hinyokika Kiyo 51:533-8. 2005
    ..Two patients achieved CR and maintained a tumor-free status beyond 14 months, suggesting that the intravesical gemcitabine is a promising salvage therapy for BCG-refractory superficial bladder cancer...
  51. ncbi Capsaicin receptor TRPV1 in urothelium of neurogenic human bladders and effect of intravesical resiniferatoxin
    Apostolos Apostolidis
    Department of Uro Neurology, National Hospital for Neurology and Neurosurgery, London, United Kingdom
    Urology 65:400-5. 2005
    ..In patients with NDO, TRPV1 suburothelial nerve density is increased, which is reversed by successful treatment with intravesical RTX. However, the role of urothelial TRPV1 in human bladder disorders is unknown...
  52. ncbi Role of IL-12 in the induction and potentiation of IFN-gamma in response to bacillus Calmette-Guérin
    M A O'Donnell
    Division of Urology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Immunol 163:4246-52. 1999
    ..The ability of supplemental exogenous IL-12 to strongly shift this balance toward Th1 provides an immunological basis for using it in conjunction with intravesical BCG for bladder cancer immunotherapy...
  53. ncbi Intravesical therapy for superficial cancer: need for more options
    E David Crawford
    J Clin Oncol 20:3185-6. 2002
  54. pmc Human bladder cancer invasion model using rat bladder in vitro and its use to test mechanisms and therapeutic inhibitors of invasion
    C Fujiyama
    Molecular Oncology Unit, ICRF, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, OX3 9DS, UK
    Br J Cancer 84:558-64. 2001
    ..In conclusion, this model shows the urokinase system is important for bladder invasion and can be used to investigate other mechanisms of bladder cancer invasion and also for the testing of intravesical drugs...
  55. ncbi Contemporary intravesical treatment options for urothelial carcinoma of the bladder
    Stephen A Brassell
    Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Natl Compr Canc Netw 4:1027-36. 2006
    ....
  56. ncbi 15-year experience on intravesical therapy of T1G3 urinary bladder cancer: a conservative approach
    Chi Wai Cheng
    Department of Surgery, Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China
    Jpn J Clin Oncol 34:202-5. 2004
    ....
  57. ncbi Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression
    A Bohle
    HELIOS Agnes Karll Hospital, Bad Schwartau, Germany
    Urology 63:682-6; discussion 686-7. 2004
    ..To compare the therapeutic efficacy of intravesical bacille Calmette-Guérin (BCG) with mitomycin C (MMC) on progression of Stage Ta and T1 bladder carcinoma...
  58. ncbi [A case of transitional cell carcinoma with squamous differentiation which developed squamous cell carcinoma in situ in the clinical course]
    Shimpei Sugiura
    The Department of Urology, Graduate School of Medicine, Yokohama City University
    Hinyokika Kiyo 52:715-8. 2006
    ..The diagnosis of SCC in situ of bladder is difficult, and this may contribute to its rarity...
  59. ncbi [Focus on tumor immunology of transitional cell carcinoma]
    P J Olbert
    Klinik für Urologie und Kinderurologie, Philipps Universitat Marburg
    Urologe A 46:1135-7. 2007
  60. ncbi Bacillus Calmette-Guérin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression
    P Andius
    Department of Urology, Sahlgrenska University Hospital, Goteborg, Sweden
    BJU Int 93:980-4. 2004
    ..To report prognostic factors for time to recurrence and progression after bacillus Calmette-Guérin (BCG) prophylaxis in patients with stage Ta/T1 papillary bladder cancer...
  61. ncbi Bacillus Calmette-Guérin-induced granulomatous hepatitis in a patient with a superficial bladder carcinoma
    Steven M Van Outryve
    Department of Gastroenterology and Hepatology, University Hospital of Antwerp, University of Antwerp, Belgium
    Eur J Gastroenterol Hepatol 16:1027-32. 2004
    ..This suggests that the BCG hepatitis was at least partially caused by a hypersensitivity reaction. Our patient is the first reported case of BCG hepatitis with histological follow-up under therapy...
  62. ncbi Adjuvant intravesical therapy based on an in vitro cytotoxicity assay in the management of superficial transitional cell cancer of the urinary bladder
    Sunita Saxena
    Institute of Pathology, ICMR, New Delhi, and Safdarjang Hospital, New Delhi, India
    BJU Int 98:1012-7. 2006
    ..To investigate the utility of an individualized chemo/immunotherapy regimen of intravesical therapy based on the results of an assessment of in vitro cytotoxicity...
  63. ncbi [Initial conservative treatment for grade 3 Ta-1 superficial bladder cancer]
    Kiyohide Fujimoto
    The Department of Urology, Nara Medical University
    Hinyokika Kiyo 52:433-8. 2006
    ..Since BCG therapy following TURBT significantly reduced the risk of recurrence and progression, adjuvant BCG therapy is considered to be the most promising initial conservative treatment for G3 Ta-1 bladder cancers...
  64. ncbi Transient anuria requiring nephrostomy after intravesical bacillus Calmette-Guérin instillations for superficial bladder cancer
    Tomoyuki Kaneko
    Department of Urology, Japanese Red Cross Medical Center, Tokyo, Japan
    Int J Urol 13:294-5. 2006
    ..Although BCG intravesical instillation after nephroureterectomy is a common practice, special care should be taken of renal function in patients with unilateral kidney during BCG therapy...
  65. ncbi The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy
    Fadi N Joudi
    University of Iowa Holden Comprehensive Cancer Center and Department of Urology, Iowa City, Iowa 52242 1089, USA
    J Urol 175:1634-9; discussion 1639-40. 2006
    ..We determined the influence of age on response to intravesical immunotherapy in patients with superficial bladder cancer...
  66. ncbi Sustained prophylactic effect of intravesical bacille Calmette-Guérin for superficial bladder cancer: a smoothed hazard analysis in a randomized prospective study
    Shiro Hinotsu
    Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan
    Urology 67:545-9. 2006
    ..To ascertain the sustained prophylactic effect of intravesical bacille Calmette-Guérin (BCG) after transurethral resection of bladder tumor (TURBT), we compared the estimation of the duration of the effect with that of doxorubicin...
  67. ncbi Intravesical gemcitabine in BCG-refractory T1G3 transitional cell carcinoma of the bladder: a pilot study
    Mauro Gacci
    Department of Urology, University of Florence, Florence, Italy
    Urol Int 76:106-11. 2006
    ..The aim of this pilot study is to analyze the safety and short-term efficacy of gemcitabine (GEM) as salvage intravesical therapy in a very selected population of bacille Calmette-Guérin (BCG)-resistant T1G3 patients...
  68. ncbi Conservative treatment of high grade superficial bladder tumours
    Alberto Trinchieri
    SC Urologia, Ospedale A Manzoni, Lecco
    Arch Ital Urol Androl 77:215-8. 2005
    ..To review our previous experience in the treatment of high grade superficial bladder tumour...
  69. ncbi Treatment of BCG failures with intravesical BCG/Interferon: the University of Montreal experience
    Pierre I Karakiewicz
    Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Outcomes Unit, University of Montreal Health Center, Quebec, Canada
    Can J Urol 13:3189-94. 2006
    ..We assessed recurrence-free survival in patients treated with intravesical BCG/Interferon (IFN) for non-muscle invasive, BCG refractory, transitional cell carcinoma (TCC) of the urinary bladder at our local institution...
  70. ncbi Tubercular prostatic abscess as a complication of intravesical bacillus Calmette-Guérin immunotherapy
    Thomas R Aust
    Department of Urology and General Surgery, Whiston Hospital, Merseyside, UK
    Int J Urol 12:920-1. 2005
    ..We report a case of tubercular prostatic abscess in a patient who had undergone intravesical bacillus Calmette-Guérin immunotherapy for bladder carcinoma in situ. The abscess required surgical drainage and antituberculous treatment...
  71. ncbi [Clinical investigation on the effect of intravesical instillation of antifibrinolytic agents with bacillus Calmette-Guerin on preventing bladder cancer recurrence]
    Guo Qing Ding
    Department of Urology, Sir Run Run Shaw Hospital of Medical School, Zhejiang University, Hangzhou 310016, China
    Zhonghua Wai Ke Za Zhi 43:1457-60. 2005
    ..To investigate the effect of intravesical instillation of antifibrinolytic agents with bacillus Calmette-Guerin (BCG) on preventing recurrence of superficial bladder transitional cell carcinoma (BTCC) after surgical management...
  72. ncbi Bladder cancer: current optimal intravesical treatment
    Donald L Lamm
    BCG Oncology, PC, Phoenix, AZ, USA
    Urol Nurs 25:323-6, 331-2. 2005
    ..Side effects of BCG immunotherapy can be decreased by logarithmic reductions in dose. Patients who fail BCG may be rescued with BCG plus interferon alfa or radical cystectomy...
  73. ncbi [International Consensus Panel--treatment strategies for superficial bladder cancer]
    Sabine Adler
    Aktuelle Urol 37:320-3; discussion 322-3. 2006
  74. ncbi Bladder cancer
    Eric S Gwynn
    Department of Urology, Wake Forest University Health Sciences, Winston Salem, North Carolina 27157, USA
    Curr Opin Oncol 18:277-83. 2006
    ..This article will review the diagnosis and management of bladder cancer at each stage, from superficial to metastatic disease with an emphasis on recent developments over the last year...
  75. ncbi Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor
    J Huguet
    Urology Service, Fundacio Puigvert, C Cartagena, 340, 08025 Barcelona, Spain
    Eur Urol 48:53-9; discussion 59. 2005
    ..To review understaging and outcome of patients who underwent radical cystectomy (RC) for high risk superficial bladder cancer after bacillus Calmette-Guérin (BCG) failure...
  76. ncbi The effect of intravesical Bacillus Calmette-Guerin instillations on the expression of inducible nitric oxide synthase in humans
    Dionisios Mitropoulos
    Department of Urology, University of Athens Medical School, Athens, Greece
    Nitric Oxide 13:36-41. 2005
    ..Inducible NOS was detected in certain tumor specimens before and after BCG treatment implying a possible involvement in pro-tumor action...
  77. ncbi Fas ligand and TNF-related apoptosis-inducing ligand induction on infiltrating lymphocytes in bladder carcinoma by bacillus Calmette-Guérin treatment
    Murat Mehmut
    Department of Urology, Juntendo University School of Medicine, Tokyo, Japan
    Urol Int 75:80-7. 2005
    ....
  78. ncbi Effects of intravesical chemotherapy and immunotherapy on semen analysis
    Gil Raviv
    Division of Andrology and Male Infertility, Department of Urology, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Urology 65:765-7. 2005
    ..To study the effect of intravesical chemo-immunotherapy on the sperm parameters of young patients...
  79. ncbi Cutaneous complications of intravesical treatments for bladder cancer: granulomatous inflammation of the penis following BCG therapy and penile gangrene following mitomycin therapy
    Faraz Kureshi
    Department of Dermatology, Mayo Clinic, Rochester, MN 55905, USA
    J Am Acad Dermatol 55:328-31. 2006
    ..Erythema involving his penis and perineum had developed within 24 hours after intravesical administration of mitomycin C, which spilled onto his perineum during catheter removal...
  80. ncbi Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory superficial bladder cancer: an investigational approach
    L G Luciani
    Division of Urology, University of Florida, Gainesville, Florida, USA
    Urology 58:376-9. 2001
    ..However, a cautious approach to this treatment modality is recommended, and very close follow-up is necessary to detect bladder recurrences and involvement of the upper tract and prostatic urethra...
  81. ncbi [Nonmuscle-invasive bladder cancer (NMIBC): when to perform cystectomy?]
    Thierry Lebret
    Service d Urologie, Hopital Foch, 40 rue Worth, Suresnes, France
    Prog Urol 18:S111-4. 2008
    ..In both cases (early, before BCG treatment, or after BCG treatment failure), this excision therapy should be practiced rapidly because the risk of progression is high and cystectomy tolerates no delay when indicated...
  82. ncbi Multivariate evaluation of factors affecting recurrence, progression, and survival in patients with superficial bladder cancer treated with intravesical bacillus Calmette-Guérin (Tokyo 172 strain) therapy: significance of concomitant carcinoma in situ
    M Takashi
    Department of Urology, Nagoya University Graduate School of Medicine, Japan
    Int Urol Nephrol 33:41-7. 2002
    ..The present findings suggest that careful follow-up is mandatory after BCG instillation therapy for patients with superficial bladder cancer and concomitant CIS because of their relatively poor prognosis...
  83. ncbi Granulomatous renal masses following intravesical bacillus Calmette Guérin therapy: the central unaffected calyx sign
    A T Senés
    Hospices Civils de Lyon, Department of Urinary and Vascular Radiology, Hopital Edouard Herriot, Lyon, F 69437, France
    Br J Radiol 80:e230-3. 2007
    ..However, the diagnostic value of this sign remains to be determined by further research...
  84. ncbi Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients
    Michael Peyromaure
    Department of Urology, Hopital Cochin, Paris, France
    J Urol 169:2110-2. 2003
    ..We report our experience with stage T1 grade 3 bladder tumors treated with bacillus Calmette-Guerin (BCG) therapy in the last 10 years...
  85. ncbi The management of superficial bladder cancer
    Guido Dalbagni
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Nat Clin Pract Urol 4:254-60. 2007
    ..The effect of intravesical immunotherapy in bladder cancer is explored as well as the role of early cystectomy...
  86. ncbi Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a nordic study
    Eero Kaasinen
    Department of Surgery, Hyvinkaa Hospital, Sairaalakatu 1, FIN 05850 Hyvinkää, Finland
    Eur Urol 43:637-45. 2003
    ....
  87. ncbi [Comparison of the effectiveness between long-term instillation of mitomycin C and short-term prophylaxis with MMC or bacille Calmette-Guérin. Study of patients with non-muscle-invasive urothelial cancer of the urinary bladder]
    H Isbarn
    Abteilung für Urologie, Universitatsklinikum Hamburg Eppendorf, Martinistrasse 52, 20246, Hamburg, Deutschland
    Urologe A 47:608-15. 2008
    ..In patients with low-risk bladder tumors, the effectiveness of six weekly MMC instillations was determined and compared with the results of patients not receiving adjuvant treatment...
  88. ncbi The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy
    Erica H Lambert
    Urology, Columbia University Medical Center, New York, NY, USA
    BJU Int 100:33-6. 2007
    ..This study examines the patterns of use of IVT in high-grade T1 bladder cancer and the subsequent impact on survival for patients ultimately proceeding to radical cystectomy (RC)...
  89. ncbi Clinical outcome of conservative therapy for stage T1, grade 3 transitional cell carcinoma of the bladder
    Isao Hara
    Department of Urology, Kobe University School of Medicine, Kobe, Japan
    Int J Urol 10:19-24. 2003
    ....
  90. ncbi [The bacillus Calmette-Guérin as immunomodulator in bladder cancer]
    Luis Gabriel Vázquez-Lavista
    Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Tlalpan, Mexico, D F
    Rev Invest Clin 59:146-52. 2007
    ..Among all the neoplasms only in superficial bladder cancer the BCG is proved to be effective...
  91. ncbi [Prevention of Bacillus Calmette-Guérin immunotherapy complications]
    Marc Colombel
    Service d urologie et de chirurgie de la transplantation, Hopital Edouard Herriot, 5 pl Arsonval, Lyon, France
    Prog Urol 18:S105-10. 2008
    ..The number of class III side effects requiring antitubercular treatment was also reduced in the patients in this study who had received ofloxacin...
  92. ncbi [Treatment and follow-up of superficial bladder cancer]
    Mika Raitanen
    Duodecim 118:903-9. 2002
  93. ncbi Long-term follow-up of intravesical bacillus Calmette-Guérin treatment for superficial transitional-cell carcinoma of the bladder involving the prostatic urethra
    Jonathan Harris Taylor
    Department of Urology, Eastern Virginia Medical School, Norfolk, VA 23501, USA
    Clin Genitourin Cancer 5:386-9. 2007
    ..We report long-term experience with BCG in this subset of patients with >5-year follow-up...
  94. ncbi [BCG infection of the glans penis after intravesical BCG therapy]
    N Michelet
    Service de Dermatologie, Hopital Fournier, CHU de Nancy, 36, quai de la Bataille, 54035 Nancy Cedex, France
    Ann Dermatol Venereol 135:479-83. 2008
    ..Therapy involves intravesical instillation of live attenuated Calmette-Guérin bacilli. BCG infection of the glans is a rare local complication associated with this treatment, two cases of which are reported below...
  95. ncbi Effect of intravesical treatment of transitional cell carcinoma with bacillus Calmette-Guerin and mitomycin C on urinary survivin levels and outcome
    Derek A Hausladen
    Department of Surgery, Section of Urology, Yale University School of Medicine, PO Box 208041 YPB 3, New Haven, CT 06520 8041, USA
    J Urol 170:230-4. 2003
    ..The presence of urine survivin in patients with TCC who receive intravesical instillation of bacillus Calmette-Guerin or mitomycin C may predict recurrence...
  96. ncbi [Urothelial carcinoma--fever and weight loss after intravesical instillation of BCG]
    R J Piso
    Medizinische Klinik, Kantonsspital Olten
    Praxis (Bern 1994) 97:901-4. 2008
    ..Under treatment with Rifampicine, Isoniazid and Ethambutol the patient recovered within a short time and the follow up chest-x-ray became normal. A supplementary steroid therapy was not needed...
  97. ncbi Do bacteriostatic urethral lubricants affect the clinical efficacy of intravesical bacillus Calmette-Guérin therapy?
    H Loertzer
    Department of Urology and Pediatric Urology, Klinikum Offenburg, Offenburg, Germany
    Urology 57:900-5. 2001
    ..To investigate the effect of a bacteriostatic urethral lubricant on the clinical efficacy of intravesical bacillus Calmette-Guérin (BCG) therapy...
  98. ncbi T1G3 transitional cell carcinoma of the bladder: recurrence, progression and survival
    M Peyromaure
    Department of Urology, Cochin Hospital, Paris, France
    BJU Int 93:60-3. 2004
    ..To report our experience with T1G3 bladder tumours over the last 10 years...
  99. ncbi Clinical utility of fluorescent in situ hybridization for the surveillance of bladder cancer patients treated with bacillus Calmette-Guérin therapy
    Lourdes Mengual
    Department of Urology, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, Universitat de Barcelona, Spain
    Eur Urol 52:752-9. 2007
    ..To evaluate the use of a multiprobe fluorescent in situ hybridization (FISH) assay for determining the response of patients with high-risk superficial bladder tumour (HRSBT) to bacillus Calmette-Guérin (BCG) therapy...
  100. ncbi Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma
    Martin G Friedrich
    Department of Urology, University Hospital Hamburg Eppendorf, Hamburg, Germany
    Eur Urol 52:1123-29. 2007
    ....
  101. ncbi Tolerability of bacille Calmette-Guérin maintenance therapy for superficial bladder cancer
    F Saint
    Service d'Urologie, , , Lyon, France
    Urology 57:883-8. 2001
    ....

Research Grants54

  1. Targeted siRNA nanotechnology for intravesical treatment of urologicaldiseases
    Robert M Weiss; Fiscal Year: 2010
    ..Our first test of these nanoparticles will use a mouse model of bladder cancer. Thus, we can determine the therapeutic potential of siRNA for treatment of urologic diseases. ..
  2. Novel Glycosaminoglycan Derivatives for Treatment of Bladder Inflammation
    JUSTIN RODNEY SAVAGE; Fiscal Year: 2011
    ..The ultimate goal of this proposal is to both gain a better understanding of bladder inflammatory pathogenesis, and to provide a safe and effective new treatment for the many patients who suffer from PBS/IC. ..
  3. Novel IL-15 Superagonist Therapy for Bladder Cancer
    Hing C Wong; Fiscal Year: 2011
    ..Immunotherapy usually consists of intravesical administration of Bacillus Calmette-Guerin (BCG), a live, attenuated bacterium...
  4. Bladder drug delivery using intravesical liposomes to treat overactive bladder
    JONATHAN H KAUFMAN; Fiscal Year: 2012
    ..With the support of the NIH, Lipella can become a sustainable tax paying company that improves the health care of Americans and supports the local and national economy. ..
  5. Combination chemo-siRNA gene therapy of nonmuscle-invading bladder cancer
    Ze Lu; Fiscal Year: 2012
    ..Given the extremely high lifetime health care costs for these patients (over $10 billion in 2003 dollars), an additional potential benefit is cost containment. ..
  6. Efficacy of BCG Therapy is a Function of Bladder Tumor Immune Microenvironment
    JAMES JOSEPH LEE; Fiscal Year: 2013
    ..treatment option for these non-muscle invasive bladder cancers are limited but commonly include intravesical administration of live attenuated Bacillus Calmette-Guerin (BCG)...
  7. Intravesical liposome drug delivery to treat interstitial cystitis
    Michael B Chancellor; Fiscal Year: 2012
    ..The knowledge gained as a result of conducting the experiments under this grant will confirm our hypotheses regarding the potential for liquid instillation of botulinum toxin and move toward bring a new treatment for PBS/IC. ..
  8. Investigation of a nanoparticle albumin-bound mTOR inhibitor, nab-rapamycin for t
    Neil Desai; Fiscal Year: 2013
    ..to conduct a combined phase 1/2 clinical trial to assess safety, toxicity, and efficacy of local intravesical administration of nab rapamycin in patients with NMIBC that have failed BCG treatment...
  9. Immunotherapeutic minicells for use in intermediate and high-risk non-muscle inva
    ROGER ALLEN SABBADINI; Fiscal Year: 2013
    ..The proposed product would be formulated and labeled for intravesical administration and be comprised of bacterial minicells, engineered to have enhanced anti-tumor and immunomodulatory ..
  10. PHARMACOLOGY OF NEW INTRAVESICAL THERAPEUTICS
    Trevor Sweatman; Fiscal Year: 1992
    ..The proposed work is significant in that it seeks to evaluate and develop new agents, based upon sound rationale, with superiority to those presently used in intravesical treatment of bladder cancer...
  11. Mouse Models for Interstitial Cystitis
    Edward Schwarz; Fiscal Year: 2004
    ..We will monitor plasma fluorescein following intravesical administration to assess the integrity of the bladder permeability barrier...
  12. Intravesical Liposome Treatment for Interstitial Cystitis
    Jonathan Kaufman; Fiscal Year: 2009
    ....
  13. Assessment of Altered Function in Diabetic Bladder
    Firouz Daneshgari; Fiscal Year: 2005
    ..value in normal rat after placement of suprapubic tube (SPT) for conduct of cystometrogram (CMG), after intravesical administration capsaicin, a C-fiber neuro-selective inhibiting agent, and Ice-water...
  14. P53 GENE THERAPY FOR LOCALLY ADVANCED BLADDER CANCER
    Lance Pagliaro; Fiscal Year: 2000
    ..cancer; 2) demonstrate infection of tumor cells and expression of p53 gene by adenoviral vector through intravesical administration; 3) characterize the in vivo effect of p53 gene transfer on apoptosis in bladder cancer; 4) investigate ..
  15. Intravesical rF-GMCSF and rF-TRICOM in the treatment of advanced bladder cancer
    Edmund Lattime; Fiscal Year: 2007
    ..This study, required by the FDA as it represents a first-in-man intravesical administration of recombinant poxvirus, provides us a unique opportunity to assess critical questions as to the ..
  16. Urothelial Cell Physiology in Normal and Disease States
    Ricardo Saban; Fiscal Year: 2005
    ..Scott-Hultgren (Washington U) will discuss the molecular basis of persistent bladder infections. The bladder cancer discussion will be chaired by Drs. Robert Hurst (Oklahoma U) and Jenny Southgate (U. York). ..
  17. Bladder transcriptome in experimental inflammation
    Ricardo Saban; Fiscal Year: 2007
    ..Following target validation of SSH-selected genes, a custom array will be developed. This micro array will be used to determine how the bladder transcriptome is altered by BCG therapy. ..
  18. LPS-PEPTIDE INTERACTION IN BLADDER INFLAMMATION
    Ricardo Saban; Fiscal Year: 2007
    ..Information generated by this study should elucidate whether bladder inflammatory responses, regardless of etiology, occur via a common mechanism or whether the endpoints are specific for each stimulus. ..
  19. Early-In-Life Inflammation Effects on Urinary Bladder Sensation
    Alan Randich; Fiscal Year: 2009
    ..Translation to the treatment of painful bladder syndromes like 1C would be highly probable. ..
  20. Effects of early-in-life bladder stimulation on adults
    Alan Randich; Fiscal Year: 2004
    ..Translation to the treatment of IC would be highly probable. ..
  21. Neonatal Bladder Inflammation, Opioids, and Adult Bladder Pain
    Alan Randich; Fiscal Year: 2010
    ....
  22. Interstitial Cystitis Clinical Research Network (ICCRN)
    J Nickel; Fiscal Year: 2007
    ..site with Dr. Nickel as PI has the experience, expertise and the proven ability to design, implement and enroll patients with IC in clinical strudies and will be a valuable partner in the proposed ICCRN and UCPPSCG. ..
  23. CORTICOTROPIN RELEASING HORMONE INDUCED DURA MAST CELL A
    Theoharis Theoharides; Fiscal Year: 2001
    ..They may also help explain some key events in the pathophysiology of migraines, the clinical symptoms of which are often precipitated by stress. ..
  24. Restraint stress-induced neurogenic bladder inflammation
    Theoharis Theoharides; Fiscal Year: 2006
    ..cell and urothelial NF-KB activation, as well as secretion of histamine, IL-6 or TNF-alpha induced by intravesical administration of CRH/Ucn...
  25. CHARACTERIZATION & TREATMENT OF CATEGORY III PROSTATITIS
    J Nickel; Fiscal Year: 2003
    ..Results from this 3 part study will be analyzed and correlated between groups and within groups, both concurrently and sequentially. ..
  26. 2006 AUA/SBUR Summer Research Conference "Urothelial Biology & Bladder Cancer"
    Dale Bjorling; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  27. REGULATION OF BLADDER NGF BY ESTROGEN
    Dale Bjorling; Fiscal Year: 2003
    ..The results of these investigations will provide a better understanding of the role of estrogen in bladder inflammation and should suggest new strategies for prevention or amelioration of pain associated with cystitis. ..
  28. Mast cells, antidepressants and chronic fatigue syndrome
    Theoharis Theoharides; Fiscal Year: 2007
    ..Future studies will build on these findings to develop in vitro and in vivo models of CFS and lead to clinical trials with select antidepressants or other molecules that inhibit brain mast cells. [unreadable] [unreadable] [unreadable]..
  29. Role of CD14 and TLR4 in Urothelial Response to LPS.
    Dale Bjorling; Fiscal Year: 2004
    ..The long-range goal of this research is to identify strategies to minimize pain and harmful cellular effects associated with cystitis due to LPS-producing gram-negative bacteria. ..
  30. Chronic Prostatitis Collaborative Research Network CPCRN
    J Nickel; Fiscal Year: 2007
    ..Nickel as PI has the experience, expertise and the proven ability to design, implement and enroll patients with CPPS in clinical studies and will be a valuable partner in the proposed CPCRN and UCPPSCG. ..
  31. Neurovascular and Behavorial Response to Cystitis
    DALE EDMOND BJORLING; Fiscal Year: 2010
    ..abstract_text> ..
  32. Applied Methods for Analysis of Interstitial Cystitis
    Kathleen Propert; Fiscal Year: 2004
    ..In addition, through this project, the ICDB will be maintained and made available to external investigators interested in using the data to explore specific hypotheses related to the natural history of IC. ..
  33. AFFERENT PLASTICITY UNDERLYING URETHRAL AND PELVIC PAIN
    Naoki Yoshimura; Fiscal Year: 2010
    ..This is recognized as a high priority in the urologic care of patients with IC/CPPS. ..
  34. The Role of NK-Kb signaling pathway--Intestitial Cystits
    Raymond Rackley; Fiscal Year: 2004
    ....
  35. Roles for MSX1 in vertebrate embryogenesis
    Cory Abate Shen; Fiscal Year: 2007
    ..Taken together, our focused analyses of Msx homeoproteins will provide general paradigms for addressing the functional specificities of other homeoproteins in vivo. ..
  36. INTERSTITIAL CYSTITIS TREATMENT PROTOCOLS
    Alan Wein; Fiscal Year: 2003
    ..C. patients across a large geographical area. This group's constant interaction creates a solid professional alignment that benefits patients from near and far. ..
  37. TRAINING IN UROLOGY
    Alan Wein; Fiscal Year: 2003
    ..At each step the trainees will be advised by experienced investigators. It is expected that in return the clinician's will offer to the laboratory insight into the fundamental clinical problems facing the specialty of urology. ..
  38. Lower urinary tract dysfunction in Parkinson's disease
    Naoki Yoshimura; Fiscal Year: 2003
    ..This is a high priority in the urologic care of patients with Parkinson's disease. ..
  39. Bladder Pain Gene Therapy with Pro-opiomelanocortin cDNA
    Naoki Yoshimura; Fiscal Year: 2004
    ..This research project is important to provide a solid basis for potential future clinical application. ..
  40. Therapeutic Targeting Agents for Bladder Cancer
    Yi Luo; Fiscal Year: 2005
    ..abstract_text> ..
  41. Broad-Spectrum Antagonist of Superantigen Toxins
    Raymond Kaempfer; Fiscal Year: 2008
    ..A superantigen therapeutic resulting from the proposed effort offers a special opportunity in biodefense. PERFORMANCE SITE ========================================Section End=========================================== ..
  42. Afferent modulation in bladde dysfunction
    Naoki Yoshimura; Fiscal Year: 2007
    ..abstract not provided ..
  43. RB4 Intravesical Gene Therapy: Mechanisms of Cell Death
    William Benedict; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  44. Interstitial Cystitis Clinical Research Network
    Christopher Payne; Fiscal Year: 2007
    ..abstract_text> ..
  45. Noninvasive Diagnosis of Early Bladder Cancers with Optical Coherence Tomography
    Yingtian Pan; Fiscal Year: 2007
    ..Our preliminary results clearly demonstrate the potential value to provide urologists with rapid, noninvasive diagnosis of abnormalities. No other technique offers this potential at present. ..
  46. Pharmacology of Nonsteroidal Androgen Receptor Ligands
    James Dalton; Fiscal Year: 2007
    ..e., the ability to maintain prostate and muscle size) are a result of differences in pharmacologic potency, tissue amplification (e.g., 5a-reductase), or drug exposure. ..
  47. BCG in Endogeneous and Exogenous Antigen-Induced T Cell
    Yi Luo; Fiscal Year: 2005
    ..abstract_text> ..
  48. Nitric oxide in bladder neural-epithelial signaling
    Lori Birder; Fiscal Year: 2005
    ..Elucidation of mechanisms impacting on urothelial function may provide insights into the pathology of bladder dysfunction. ..
  49. PHYSICIAN AND SCIENTIST TRAINING IN UROLOGICAL RESEARCH
    Alan Wein; Fiscal Year: 2007
    ..Funding is sought for two years of support for three trainees annually. ..
  50. Neurophysiology and Biomechanics of Urethra in Stress Urinary Incontinence
    Naoki Yoshimura; Fiscal Year: 2008
    ..This is recognized as a high priority in the urologic/gynecologic care of SUI patients. [unreadable] [unreadable]..
  51. Treatment of Persistent Postprostatectomy Incontinence
    Patricia Goode; Fiscal Year: 2007
    ..abstract_text> ..
  52. Roles of Nkx3.1 in prostate development and cancer
    Cory Abate Shen; Fiscal Year: 2007
    ..1 protein expression. These mice will provide a valuable model for exploring the reversibility of prostate carcinogenesis in vivo. ..
  53. Volume-Outcomes in Incontinence Surgery
    Jennifer Anger; Fiscal Year: 2005
    ..The primary outcome will be re-operation rates, repeat sling procedures (for failures), and other postoperative complications, stratified by high and low volume surgeons and hospitals. ..
  54. Urine Antiproliferative Peptide in Interstitial Cystitis
    Susan Keay; Fiscal Year: 2009
    ..Data from these studies should yield valuable information regarding the structure and mechanism of activity for APF, and may also lead to the identification of potential therapies for this disorder. ..